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A B S T R A C T   
Repolarization alternans, a periodic oscillation of long-short action potential duration, is an important source of 
arrhythmogenic substrate, although the mechanisms driving it are insufficiently understood. Despite its rele-
vance as an arrhythmia precursor, there are no successful therapies able to target it specifically. We hypothesized 
that blockade of the sodium‑calcium exchanger (NCX) could inhibit alternans. The effects of the selective NCX 
blocker ORM-10962 were evaluated on action potentials measured with microelectrodes from canine papillary 
muscle preparations, and calcium transients measured using Fluo4-AM from isolated ventricular myocytes paced 
to evoke alternans. Computer simulations were used to obtain insight into the drug’s mechanisms of action. 
ORM-10962 attenuated cardiac alternans, both in action potential duration and calcium transient amplitude. 
Three morphological types of alternans were observed, with differential response to ORM-10962 with regards to 
APD alternans attenuation. Analysis of APD restitution indicates that calcium oscillations underlie alternans 
formation. Furthermore, ORM-10962 did not markedly alter APD restitution, but increased post-repolarization 
refractoriness, which may be mediated by indirectly reduced L-type calcium current. Computer simulations 
reproduced alternans attenuation via ORM-10962, suggesting that it is acts by reducing sarcoplasmic reticulum 
release refractoriness. This results from the ORM-10962-induced sodium‑calcium exchanger block accompanied 
by an indirect reduction in L-type calcium current. Using a computer model of a heart failure cell, we further-
more demonstrate that the anti-alternans effect holds also for this disease, in which the risk of alternans is 
elevated. Targeting NCX may therefore be a useful anti-arrhythmic strategy to specifically prevent calcium 
driven alternans.   
1. Introduction 
The cardiac sodium‑calcium exchanger (NCX) exchanges a single 
calcium ion for three sodium and is therefore electrogenic [1]. It links 
cardiac electrophysiology with cellular calcium handling as NCX is the 
primary path of calcium efflux from the cell [2]. The exchange may 
proceed in either direction, depending on ionic concentrations and 
membrane potential: forward mode (calcium efflux) or reverse mode 
(calcium influx). Given its central role in cellular function, it is not 
surprising that NCX is implicated in multiple arrhythmogenic phenom-
ena, such as early afterdepolarizations [3], delayed afterdepolarizations 
[4], and alternans [5]. Experimental research of NCX was until recently 
complicated by a lack of specific NCX blockers [6]. However, the NCX 
blocker ORM-10962 has been shown to be a useful tool for the study of 
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NCX, given its selectivity and lack of strong preference to either mode of 
NCX [6]. While this drug does not block the L-type calcium current 
(ICaL), it was nevertheless observed to reduce it indirectly, likely via 
calcium-driven inactivation [7]. ORM-10962 has been applied to the 
study of afterdepolarizations [6], but not cardiac alternans, which is the 
focus of this study. 
Action potential duration (APD) alternans is the oscillation of long 
and short APD at rapid heart rates, and has been shown to precede the 
formation of arrhythmia in the heart [8,9]. Multiple studies suggest that 
the mechanisms of arrhythmia induction following alternans are linked 
to increased dispersion of repolarization [10–12]. The vulnerability of 
hearts to alternans considerably increases in many heart diseases, such 
as heart failure [13], hypertrophic cardiomyopathy [14], or myocardial 
infarction [12,15,16]. APD alternans typically occurs concurrently with 
oscillation of calcium transient (CaT) amplitude [17,18], presenting the 
question which of these two is the main driver. It is possible that steep 
restitution of APD drives alternans [19]. However, further studies sug-
gested that CaT oscillations are the primary driver [20], subsequently 
translated into APD alternans by NCX and other calcium-sensitive cur-
rents [21]. 
Given the possible involvement of NCX in alternans, ORM-10962 
may be a promising antiarrhythmic strategy, particularly in cardiac 
diseases with elevated risk of alternans. However, the precise effect of 
NCX blockade on alternans is not necessarily straightforward. If we 
assumed a constant level of CaT alternans, NCX blockade would clearly 
reduce APD alternans. However, the assumption of constant CaT alter-
nans following NCX blockade may not hold. On the one hand, it has been 
suggested that CaT alternans occurs if there is a steep dependence of 
calcium efflux from the cell on the SR calcium content [22]. Inhibition of 
NCX will make this dependence less steep and might therefore decrease 
alternans. On the other hand, CaT alternans is mostly thought to arise 
from increased sarcoplasmic reticulum release and CaT amplitude 
[11,23]. Therefore, the effect of NCX block, reducing efflux and locking 
more calcium in the cell, could be an increase in SR loading and thus 
release, increasing alternans. This could subsequently negate the 
reduction in APD alternans, or even extend the presence of alternans to 
slower pacing rates, which would be proarrhythmic. The aim of this 
study was therefore to characterize the effect of NCX blockade on both 
APD and CaT alternans and provide insight into the mechanisms 
involved. 
2. Materials and methods 
2.1. Experimental methods 
2.1.1. Ethical statement 
All experiments were carried out in compliance with the Guide for 
the Care and Use of Laboratory Animals (USA NIH publication No 
85–23, revised 1996) and were approved by the Csongrád County 
Governmental Office for Food Safety and Animal Health, Hungary 
(approval No.: XIII/1211/2012). The ARRIVE guidelines were adhered 
to during the study, (NC3Rs Reporting Guidelines Working Group, 
2010). 
2.1.2. Standard microelectrode technique 
Beagle dogs of either sex weighing 8 to 16 kg obtained from a 
licensed supplier were used for the study. Following sedation of the dogs 
with xylazine (1 mg/kg, i.v.) and thiopental (30 mg/kg i.v.), each heart 
was rapidly removed through a right lateral thoracotomy and immedi-
ately rinsed in oxygenated Locke’s solution. Action potentials were 
recorded at 37 ◦C from the surface of dog right ventricular papillary 
muscles using conventional microelectrode technique. A total of n = 13 
preparations were recorded from n = 9 hearts, and clustering analysis 
was carried out to ascertain that pseudoreplication did not occur when 
more than one preparation per heart was measured (Appendix F). The 
preparations were mounted in a custom made plexiglass chamber, 
allowing continuous superfusion with O2-CO2 saturated Locke’s solution 
(containing in mM: NaCl 120, KCl 4, CaCl2 1.0, MgCl2 1, NaHCO3 22, 
and glucose 11). The pH of this solution was set between 7.35 and 7.4 
when saturated with a mixture of 95% O2 and 5% CO2 at 37 ◦C. The 
tissue samples were stimulated with constant current pulses of 1 ms 
duration at a rate of 1 Hz through a pair of bipolar platinum electrodes 
using an electrostimulator (Hugo Sachs Elektronik, model 215/II). The 
stimulus electrode was placed at the proximal site of the papillary 
muscle providing impulse propagation towards the tendons. Sharp mi-
croelectrodes with tip resistance of 10–20 MΩ, when filled with 3 M KCl, 
were connected to an amplifier (Biologic Amplifier, model VF 102). 
Voltage output from the amplifier was sampled using an AD converter 
(NI 6025, Unisip Ltd). Alternans was evoked by application of 20 beats 
at cycle lengths of 250 ms to 160 ms. Efforts were made to maintain the 
same impalement throughout the whole experiment. When the 
impalement was dislodged, an adjustment was attempted. The mea-
surements were only continued if the action potential characteristics of 
the re-established impalement deviated less than 5% from the previous 
one. APD alternans were measured at a following pre-defined pacing 
cycle lengths: 250, 230, 210, 190 and 170 ms. After recording the 
control pacing protocol, 1 μM ORM-10962 was employed and alternans 
protocol was repeated. 
2.1.3. Cell isolation 
Ventricular myocytes were enzymatically dissociated from dog 
hearts. The excised left ventricular segments were perfused through the 
left anterior descending coronary artery using a gravity flow Langen-
dorff apparatus. The perfusate was a modified Tyrode solution 
(composition in mM: NaCl 144, NaH2PO4 0.4, KCl 4.0, MgSO4 0.53, 
glucose 5.5) supplemented with 1.2 mM CaCl2, 10 mM HEPES, 20 mM 
taurine, and 1.6 mM Na-pyruvic acid (pH = 7.2 with NaOH). After 
removal of the blood the perfusate was switched for 10 min to nominally 
Ca2+-free Tyrode. Dispersion of cells was achieved by application of 0.5 
g/l collagenase (Sigma type I) for 40 min in the presence of 50 μM CaCl2. 
During the isolation procedure the solutions were gassed with 100% 
oxygen and the temperature was maintained at 35 ◦C. Finally, the tissue 
was minced and gently agitated. The cells, freshly released from the 
tissue, were stored at room temperature before use. At least 60% of the 
cells were rod-shaped and showed clear striation when the external Ca2+
was restored. One drop of cell suspension was placed in a transparent 
recording chamber mounted on the stage of an inverted microscope 
(Olympus IX71, Olympus, Tokyo, Japan), and individual myocytes were 
allowed to settle and adhere to the chamber bottom for at least 5–10 min 
before superfusion was initiated and maintained by gravity. Only rod- 
shaped cells with clear striations were used. HEPES-buffered Tyrode’s 
solution served as the normal superfusate. 
2.1.4. S1S2 restitution 
In order to determine the recovery kinetics of APD80 extra test action 
potentials were elicited by using single test pulses (S2) in a preparation 
constantly paced in a basic cycle length of 1000 ms. The S1-S2 interval 
was increased progressively from APD80 − 50 ms to APD80 + 500 ms. 
The effective refractory period was defined as the longest S2 coupling 
interval that did not lead to an action potential developing in the tissue 
sample. In addition, postrepolarization refractoriness (PRR) was infer-
red from the S1S2 restitution protocol. PRR was defined as the shortest 
diastolic interval between the S1 and S2 stimuli that led to a propagation 
of an action potential (this corresponds to ERP - APD(S1), where APD 
(S1) is the APD80 of the S1 stimulus and ERP is the effective refractory 
period). 
2.1.5. Calcium transient measurements 
CaTs were recorded using a Ca2+-sensitive fluorescent dye, Fluo-4 
AM simultaneously with ionic current measurements. Cardiomyocytes 
isolated from the left ventricle were loaded with 5 μM Fluo 4-AM for 15 
min at room temperature in the dark. Loaded cells were mounted in a 
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low volume imaging chamber (RC47FSLP, Warner Instruments) and 
field stimulated with a pair of platinum electrode. Frequency pattern 
was applied by using Evokewave v1.49 software. Fluorescence mea-
surements were performed on the stage of an Olympus IX 71 inverted 
fluorescence microscope. The dye was excited at 480 nm and the emitted 
fluorescence is detected between 515 and 550 nm. Optical signals were 
sampled at 1 kHz and recorded by a photon counting photomultiplier 
module (Hamamatsu, model H7828). Data acquisition and analysis were 
performed using Axon Digidata 1550B System. All CaTs were measured 
at 37C◦. In order to calibrate the records, alterations in Ca2+i were 
calibrated after disruption of the cells by a patch pipette, by using the 
following equation for Fluo-4: 
Ca2+ i = Kd*(F − Fmin)
/
(Fmax − F)
2.2. Signal analysis 
APD alternans was extracted based on four consecutive action po-
tentials as the difference between average APDs of even and odd AP. The 
electrophysiological measurements were at most 1 s long, yielding four 
action potentials at the longest cycle length of 250 ms. A custom-written 
Matlab script was used for this purpose. The four beats were smoothed 
via zero-phase digital filtering (@filtfilt in Matlab) with diameter of 10 
ms. The baseline of such signal was taken as the 2.5-percentile of the 
signal, and the peak as the 99.5-percentile. Based on this, the thresholds 
(membrane potential levels at which APD is measured) for APD25 (25% 
repolarization, i.e., mainly plateau duration) and APD80 (80% repo-
larization) were computed. Each threshold was applied to the whole 4- 
beat recording, rather than being estimated from each AP separately. 
This is to avoid “threshold alternans” where alternation of AP peak 
potential induces alternation of the thresholds, which taints the esti-
mation of the degree of alternans. In the majority of recordings of APD 
alternans, the basic cycle lengths used were 170, 190, 210, 230, and 250 
ms. In several preparations, slightly different basic cycle lengths were 
used – in such a case, the alternans at the above-mentioned basic cycle 
lengths was obtained interpolation (e.g., alternans at 170 ms basic cycle 
length would be obtained as the average of alternans at 160 and 180 ms 
if these two were available). When diastolic intervals were measured, 
they were taken as the periods between segments corresponding to 
APD80 of action potentials. The first and last such diastolic intervals 
were discarded as they are typically incomplete. 
Calcium alternans in the experiments was based on six consecutive 
CaTs, where the average CaT amplitude was computed for even and odd 
beats. The signal was separated into CaTs using the ‘comb’ algorithm for 
fixed-rate pacing [24]. The amplitude of a single CaT was estimated as 
the difference between the peak and the minimum directly preceding 
the given CaT (i.e., it is the CaT upstroke amplitude). CaT alternans is 
expressed as the ratio of the amplitudes of the larger to the smaller CaT. 
Three subtypes of APD alternans were defined based on the phase of 
alternans at the levels of 25% and 80% repolarization: 
• Recordings of the ’++’ alternans type manifest concurrent prolon-
gation (or concurrent shortening) by at least 3 ms both at the 25% 
and 80% repolarization level. I.e., oscillations of APD at the 25% and 
80% levels are in phase.  
• Recordings of the ’+− ’ alternans manifest concurrent prolongation 
by at least 3 ms at the 25% repolarization level and shortening by at 
least 3 ms at the 80% repolarization level (or vice versa). I.e., os-
cillations of APD at the 25% and 80% levels are in the opposing 
phase.  
• Recordings of the ’+0’ are recordings manifesting shortening or 
prolongation by at least 3 ms at the 25% repolarization level, while 
the prolongation or shortening at the 80% level is less than 3 ms. I.e., 
there is clear APD25 alternans, but not APD80 alternans. 
When analysing experimental S1S2 restitution protocol, the APD was 
measured at 80% level of repolarization using Evokewave v1.49 soft-
ware (Unisip Ltd). 
2.3. Computer simulations 
ToR-ORd, a recent robustly validated human ventricular myocyte 
model, was used throughout this study [25], being selected for its 
improved representation of L-type calcium current and sodium and 
calcium balance compared to its predecessors. This model is capable of 
reproducing calcium-driven alternans stemming from refractoriness of 
Ca2+ cycling in the sarcoplasmic reticulum; the mechanism is described 
in detail in [23]. It is therefore more suitable for this study than other 
human ventricular models, such as Grandi et al. [26], which does not 
manifest alternans, or Ten Tusscher et al. [27], which manifests alter-
nans, but one that is driven by APD restitution (which is shown not to be 
the key cause of alternans in the experiments in this study). Simulations 
using a human model provide a bridge for the interpretation and 
translation of the findings obtained using animal experiments towards 
clinically-relevant outcomes. The effect of ORM-10962 on ionic dy-
namics was modelled as reducing NCX availability to 50% and reducing 
ICaL availability to 65% as observed experimentally [7]. Additional ex-
periments were carried out to verify that even at rapid pacing used in 
this study, the NCX block achieved with the given ORM-10962 con-
centration is close to 50% (Appendix G). 
Originally, we also considered the most up-to-date canine model of 
the Rudy family [28]. However, when simulating the effect of ORM- 
10962, the canine model predicted a substantial APD prolongation not 
seen in our experimental data (see Fig. 3; mean APD at DI of 500 ms is 
183 ± 31 ms for ORM-10962, and 198 ± 23 ms for control; p = 0.28) or 
that of others [6]. Subsequent analysis revealed that the APD prolon-
gation in the canine model is linked to artefactual lack of IKr activation 
following AP plateau lowering (which follows from ICaL reduction). This 
is a manifestation of a problem which warranted the replacement of the 
IKr model in development of ToR-ORd [25]. For this reason, and given 
that there are no known differences between canine and human calcium 
handling pertaining to the phenomena studied there, we believe that 
ToR-ORd is the best model choice. 
The S1-S2 protocol was simulated by first prepacing the cell during 
1000 beats at 1 Hz (S1), followed by a single S2 stimulus at varying S1- 
S2 intervals = 150, 152, 154, …350, and then 400, 500, 600, …, 1000. 
For this protocol, the INa conductance was reduced to 25% to more 
clearly demonstrate the role of ICaL in cellular excitability (see Section 
3.4 for more details). The reaction to S2 stimulus was classified as an 
action potential if the peak membrane potential exceeded 10 mV. 
When evaluating ERP in single cell for the investigation of post-
repolarization refractoriness, this was defined as the longest S2 coupling 
interval that did not trigger a S2 AP. 
2.3.1. Population of models construction 
A population of ToR-Ord models was created by simulating 5000 
models with perturbation of conductances of the following ionic cur-
rents: INa, INaL, ICaL, Ito, INaK, INaCa, IKr, IKs, IK1. Each current in each 
model was sampled in the 50–200% range (corresponding to a multi-
plier of 0.5–2), using symmetric sampling where the probability of x is 




, where U(0,1) is random number uniformly sampled 
between 0 and 1. It can be seen that e.g. for the random number being 
0 and 1, the resulting values of multiplier are 0.5 and 2 respectively. This 
approach ensures that approximately half of multipliers is below 1 and a 
half is above 1 (as opposed to uniformly sampling between 0.5 and 2 
straight away, which will assign only a third of generated values below 
1, and two thirds above 1, overrepresenting current conductance in-
crease on average). 
A calibration to human experimental data was carried out using the 
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following criteria: 
• APD40, APD50, APD90, triangulation (APD90-APD40), peak up-
stroke velocity, and resting potential within experimental range, as 
in population of models construction in [29].  
• Calcium transient duration is within standard deviation of the data in 
[30].  
• The model manifests alternans at at least one of the tested basic cycle 
lengths (240, 250, …, 340 ms). 
A total of 684 models fulfilled all the criteria, and these were sub-
sequently used to compare alternans onset between the model and four 
simulated versions of NCX blockade (50% NCX availability + 50, 65, 70, 
and 80% ICaL availability respectively). 
2.3.2. Heart failure simulations 
Heart failure remodelling was introduced in the ToR-ORd model, 
mainly based on studies summarized and used in [31]. Similarly to their 
study, we increased the conductances of INaL by 80%, INaCa by 50%, ICab 
by 53%, and reduced the conductance of Ito by 60%, IK1 by 32%, and INaK 
by 30%. In addition, the time constant of INaL inactivation τhL was 
increased by 80%, CaMKII autophosporylation rate was increased by 
50%, and Jleak (leak from NSR to main cytosolic compartment) by 30%. 
The rate of SR reuptake via SERCA pumps Jup was reduced by 30% and 
SR release was made 20% more sensitive to calcium in the junctional SR. 
In addition, we added an explicit leak flux Jleak,JSR to the ryanodine 
receptor to represent increased ryanodine receptor leakiness present in 
heart failure [32]. The formulation is based on the Jleak,JSR in [28]: 
e
CaJSR
20 ∙(CaJSR − CaSS)
CaJSR is the calcium concentration in the junctional SR, and CaSS is 
the calcium concentration in the junctional subspace. 
Furthermore, the time constant of SR release was increased six-fold 
to represent the phenotype of SR release present in heart failure, 
where calcium sparks have markedly longer time to peak and duration 
[33,34]. Its precise magnitude is however not known. This change is 
very important for the increased vulnerability of the simulated heart 
failure cell to alternans by mechanism described in [23]. 
Ultimately, the sensitivity of SR uptake to intracellular calcium 
concentration was reduced, as this was also observed in heart failure 
[35]. This was achieved by shifting the half-activation of the SERCA 




Cai + 0.00092 + 0003  
Jup,P = 2.75∙0.005425∙
Cai
Cai + 0.00075 + 0003 
The elements in bold were added to achieve the desensitization. 
2.3.3. S1S2 in simulated cardiac fibre 
The 1D fibre tissue simulations were conducted using the open- 
source software CHASTE [36]. The homogeneous monodomain 1D 
endocardial fibres had a length of 4 cm consisting of 200 nodes, with a 
conductivity of 1.64mS/cm to achieve a diffusion coefficient of 1.171 
cm2/s [37]. The 1D fibres were paced under an S1-S2 protocol: regular 
S1 stimulus was applied with a cycle length of 1000 ms for 20 beats, 
followed by a single S2 stimulus; the coupling intervals simulated were 
150, 152, 154, …, 450, and then 500, 600, …, 1000. Restitution curves 
were measured at the centre of the fibre. As in single cell restitution, INa 
conductance was reduced to 25%. 
When evaluating ERP in a fibre for the investigation of post-
repolarization refractoriness, this was defined as the longest S2 coupling 
interval that did not trigger a S2 AP in the cell at position x = 2 cm. 
2.4. Statistical methods 
Paired t-test was used for paired comparisons (Figs. 1B,C, 3B,C, 6A). 
Wilcoxon rank-sum test was used for unpaired comparisons (Fig. 1E), 
used over unpaired t-test given markedly different variance between the 
groups. The statistical significance level used was α = 0.05. 
3. Results 
3.1. NCX blockade via ORM-10962 inhibits alternans of APD and CaTA 
APD alternans was measured in canine papillary muscle preparations 
at two repolarization levels (25% and 80%), both in control conditions 
and after the application of ORM-10962 (Fig. 1A). ORM-10962 signifi-
cantly attenuated APD25 at most basic cycle lengths (Fig. 1B). Alternans 
of APD80 was significantly attenuated only at the slowest pacing (basic 
cycle lengths 230 and 250) (Fig. 1C). To complement the electrophysi-
ological recordings of alternans, calcium imaging measurements were 
additionally taken in isolated cells. These recordings confirmed that 
calcium transient amplitude alternans was also potently and signifi-
cantly attenuated by ORM-10962 at 230 ms bcl (Fig. 1D,E). 
Investigating the relationship between APD25 and APD80 alternans, 
we observed three types of behaviour. In the ’++’ type, the APD is 
prolonged/shortened at both levels of repolarization, at the same time 
between subsequent action potentials (Fig. 2A). In type ’+− ’, the APD is 
prolonged at one level, but shortened at the other one (Fig. 2B). Ulti-
mately, in type ’+0’, there is visible alternans at the APD25 level, but 
none at APD80 (Fig. 2C). All three types were present in control and 
ORM-10962 conditions, with ORM-10962-treated cells showing fewer 
recordings of the ’++’ type and more of the ’+− ’ type (Fig. 2D,E). The 
analysis of transitions of alternans types before and after ORM-10962 
treatment shows that many ’++’ recordings changed into the ’+0’ 
type with ORM10962, while ’+0’ recordings either stayed in the same 
class or transitioned towards the ’+− ’ type (Fig. 2F). We can thus see a 
pattern where a given APD25 prolongation during alternans is associ-
ated with less APD80 prolongation or even with its shortening following 
ORM-10962 treatment. 
We carried out additional exploration of the effect of ORM-10962 on 
the three different alternans types reported above (Appendix B). 
Consistent with near-universal alternans attenuation observed for 
APD25 (Fig. 1B), alternans was generally attenuated by ORM-10962 for 
all alternans types (Appendix A, Supplementary Fig. 1A). However, the 
situation is different for alternans of APD80, where there was a marked 
difference in response of preparations manifesting ’++’ and ’+0’ 
alternans before the drug treatment (the number of cases of ’+− ’ 
alternans is too low to allow drawing conclusions). Whereas alternans 
was attenuated in the vast majority of cases of ’++’ alternans (18 
attenuated, 1 unchanged, 1 promoted; mean response is attenuation by 
4.9 ms), the situation is much less clear for the ’+0’ type (8 attenuated, 3 
unchanged, 9 promoted; mean response is promotion by 1.47 ms) (Ap-
pendix A, Supplementary Fig. 1B). In addition, the ’++’ type was 
prevalent for the slower pacing rates (basic cycle length of 230 or 250), 
but not for the faster ones (Appendix A, Supplementary Fig. 1C), which 
helps to explain why APD80 alternans attenuation was observed only for 
the slower pacing rates in Fig. 1C. In terms of absolute magnitude, 
APD80 alternans was the greatest in the ’++’ type, while being by 
definition minimal in the ’+0’ type (Appendix A, Supplementary Fig. 
1D). 
3.2. Alternans attenuation via ORM-10962 is not due to restitution of 
APD 
We subsequently sought to determine the mechanism of alternans 
formation and its attenuation. We first explored the restitution-driven 
mechanism of APD alternans [19]. There the alternans arises from the 
slope of the restitution curve exceeding 1 for diastolic intervals (DI) 
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between the alternating beats. We measured restitution curves using the 
S1-S2 protocol in canine ventricular muscle preparations (Fig. 3A). 
Before ORM-10962 application, 5 out of 8 hearts did contain an interval 
of the restitution curve with slope > 1 and 3 out of 8 contained such an 
interval after ORM-10962 application. The change in the peak slope 
after the application of ORM-10962 was not statistically significant 
(Fig. 3B, p = 0.84). The longest diastolic interval with slope > 1 was 
extracted in each recording (Fig. 3C), with the hypothesis that if dia-
stolic intervals observed during alternans fall within the zone of resti-
tution slope > 1, the restitution is a plausible explanation of APD 
alternans. The fact that in no recording the zone of slope > 1 extended 
beyond DI = 60 ms essentially excludes the restitution-based mechanism 
as the driver of alternans in our data, given that DI < 60 ms were rarely 
observed in alternans recordings. Only 4 out of 68 recordings of bcl ≥
210 ms had the shorter DI below the observed maximum of 60 ms, and 
none had the shorter DI below 35 (median of points shown in Fig. 3C; 
both groups pooled). APD alternans was also present at 250 ms bcl 
pacing, where the shorter DIs are typically close to 100 ms, i.e., both 
short and long DI were outside the zone of steep restitution. Together, 
these observations indicate that alternans we observed is not driven by 
APD restitution, but potentially by calcium oscillations. 
3.3. Computational simulations illuminate the role of altered balance of 
calcium handling in alternans attenuation 
Using the human ventricular myocyte ToR-ORd model [25], we then 
ran simulations of the action of ORM-10962 on calcium-driven alternans 
to gain further mechanistic understanding into the attenuation of 
calcium-driven alternans. The control ToR-ORd model manifests 
calcium-driven alternans for base cycle length of 280 ms and faster 
(Fig. 4A). The mechanism is linked to refractoriness of SR calcium 
cycling: following a large release at rapid pacing, the junctional SR is not 
replenished fully before the next beat, leading to CaT amplitude oscil-
lations [23]. ORM-10962 was represented as a combined reduction of 
NCX and ICaL (Methods 1.3). To gain a broader picture of the role of ICaL 
reduction, we simulated five different levels of ICaL availability (50%, 
65%, 70%, 80%, and 100%) in addition to a 50% reduction of NCX. 
Interestingly, all studied combinations of NCX and reduced ICaL 
Fig. 1. Alternans attenuation via ORM-10962. A) Example of APD alternans at two levels (APD25 and APD80) in control condition and following ORM-10962 
exposure in muscle preparations. B) APD25 alternans at a range of pacing rates (n = 13). C) APD80 alternans at a range of pacing rates (n = 13). In B,C, paired 
t-test was used to compute the p-values. D) Example of reduction in CaT alternans in isolated cells via ORM-10962. E) Quantitative summary of CaT alternans 
(expressed as the ratio between the amplitude of the larger versus smaller CaT) without (n = 6) and with (n = 6) ORM-10962. Unpaired rank-sum test was used in E 
given different variance between control and ORM-10962. 
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Fig. 2. Distinct patterns of alternans at two repolarization levels. A-C) Examples of ’++’, ’+− ’, and ’+0’ types of alternans respectively (i.e., shortening plateau 
corresponds to prolonged, shortened, or unchanged APD at 80% level of repolarization). The three recordings shown were obtained at bcls of 250, 190, and 190 ms 
respectively. D) Correlation of the difference in consecutive APDs at repolarization levels of 25% and 80%; all tested bcls were pooled together in this plot. E) 
Composition of the three alternans types in the control condition and following ORM-10962 treatment. The lower total number of entries following ORM-10962 
stems from alternans attenuation by the compound: a recording has to manifest alternans of at least 3 ms at the APD25 level in order to be classified as one of 
the three types. F) A transition matrix encoding the change in alternans type upon ORM-10962 application. Each matrix element colour-codes the number of 
preparations manifesting a given type of alternans in the control condition (y-axis) that transitioned into a given type of alternans after ORM-10962 application 
(x-axis). 
Fig. 3. ORM-10962 and restitution properties. A) Restitution curves measured before and after application of ORM-10962 to canine tissue samples (n = 8). Thick 
lines give the median S2 APD (computed where at least 3 data points are available for the given diastolic interval). B) Paired measurements of maximum slope of the 
restitution curve before and after ORM-10962; the overlay gives mean ± SD. C) Longest diastolic interval before which the slope of restitution curve is greater than 1; 
the overlay gives mean ± SD. 
J. Szlovák et al.                                                                                                                                                                                                                                 
Journal of Molecular and Cellular Cardiology 153 (2021) 111–122
117
availability led to alternans attenuation as assessed by moving alternans 
onset to faster frequencies, or abolishing alternans altogether (Fig. 4A); 
however, the mechanisms are distinct. 
The case closest to experimental measurements is 50% NCX reduc-
tion and 65–70% ICaL availability, which exerts a small or moderate 
increase in CaT amplitude compared to control ToR-ORd cell at 1 Hz 
pacing (Fig. 4B). This agrees with a previous study on ORM-10962 
showing only a minor increase in calcium transient amplitude [6] and 
experimentally observed 65% ICaL availability for 50% NCX availability 
after ORM-10962 treatment [7], Appendix G. The mechanism of alter-
nans attenuation in such a setting is best illustrated on the case of 65% 
ICaL availability: even though the CaT amplitude is almost identical to 
the control cell, the calcium loading of the network sarcoplasmic retic-
ulum is increased at all tested pacing rates (example at 1 Hz in Fig. 4C). 
Consequently, the gradient between the network and junctional SR is 
increased, allowing faster refilling of the junctional SR, reducing SR 
refractoriness, inhibiting alternans [23]. 
A substantial increase in CaT amplitude compared to control cell is 
observed when ICaL availability is 80% or 100% (Fig. 4B), and in these 
cases, no alternans is found (Fig. 4A). Inspection of the contents of 
junctional SR at base cycle length 280 (where the control model already 
shows alternans) reveals that the junctional SR is fully depleted in both 
beats in such conditions (Fig. 4D). The phenomenon of full SR depletion 
and consequent alternans abolishment in simulations was characterised 
previously [23], but its physiological relevance is debatable. Impor-
tantly, we note that in the cases of 65% and 70% ICaL availability 
described above, the junctional SR is clearly not fully depleted at 280 ms 
bcl (Fig. 4D), verifying that the full depletion of junctional SR is not the 
Fig. 4. Simulations of alternans and ORM-10962. A) The longest basic cycle length at which was alternans detected in control condition and several combinations of 
NCX and ICaL availability representing simulated ORM-10962 (NA = not available = no alternans). See Appendix C for a full frequency-alternans relationship at all 
the studied conditions. B) Calcium transient at 1000 ms bcl pacing. C) Calcium concentration in the network SR at 1000 ms bcl pacing. D) Calcium concentration in 
the junctional SR at 280 ms bcl pacing. E) A breakdown of the effect of five treatments simulating ORM-10962 (50% NCX availability and the five listed availabilities 
of ICaL) compared to the baseline model using a population of models approach. For each of 684 tested models in the population and for each treatment, a simulation 
was classified as ‘alternans attenuated’ if the treatment shifted alternans onset to shorter basic cycle length, ‘alternans promoted’ if alternans onset was shifted to 
longer basic cycle lengths, and ‘alternans maintained’ if alternans first appeared at the same basic cycle length. See Appendix D for a breakdown of how much was 
alternans promoted or attenuated in each condition. 
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mechanism of alternans attenuation in these cases. 
When the availability of ICaL is low (50%), alternans is also never 
present (Fig. 4A). Given the CaT amplitude is considerably diminished 
(Fig. 4B), the lack of alternans is clear: calcium alternans stems from a 
greater calcium release, and when the release is not sufficiently large, 
there is no alternans. However, no such reduction in CaT amplitude was 
observed upon ORM-10962 application [6], and so this explanation can 
be excluded. 
In order to assess the sensitivity of the results to specific parameter 
values in the ToR-ORd model, we further investigated the impact of 
simulated ORM-10962 on alternans using the population of models 
approach [29,38]. A population of 684 simulated cells calibrated to 
human experimental data was used (see Methods for details), and each 
cell was simulated in normal conditions and with five levels of ICaL 
availability accompanying a 50% NCX block as above. In all five con-
ditions, the vast majority of models showed alternans attenuation 
compared to the control model (over 88%, Fig. 4E), supporting the 
relevance of the anti-alternans effect of ORM-10962. Furthermore, 
additional analyses revealed that the mechanism underlying a substan-
tial part of the cases of alternans promotion (including all the cases of 
alternans promotion at 50% or 65% ICaL) has debatable relevance (Ap-
pendix B). 
3.4. Validation of the anti-alternans effect of ORM-10962 in simulated 
heart failure 
Even though alternans can usually arise even in healthy 
myocardium, its importance is even greater in cardiac diseases such as 
heart failure with reduced ejection fraction, where it manifests at slower 
pacing rates, often preceding the formation of ventricular fibrillation 
[8,13]. To assess the anti-alternans potential of ORM-10962 in heart 
failure, we incorporated a broad range of experimental data on heart 
failure remodelling in the baseline ToR-ORd model (see Methods). The 
resulting model replicates key hallmarks of human heart failure, such as 
APD prolongation and loss of spike-and-dome morphology (Fig. 5A) 
[39], reduced amplitude of calcium transient, along with the prolon-
gation of its duration and time to peak (Fig. 5B) [40], and reduced 
calcium loading of the sarcoplasmic reticulum (Fig. 5C) [39]. 
Importantly, the onset of alternans in the control model (280 ms bcl) 
is shifted by heart failure remodelling to slower frequencies (330 ms bcl) 
(Fig. 5D), consistent with experimental observations [8,13]. The 
amplitude of repolarization alternans is also increased by the heart 
failure remodelling, leading to potentially greater dispersion of repo-
larization induced by alternans and thus a higher arrhythmic risk. 
Crucially, simulated ORM-10962 (using the data-driven version of 50% 
NCX and 65% ICaL availability) attenuated alternans in the failing cell, 
both with regards to the alternans onset (310 versus 330 ms) and 
amplitude at most basic cycle lengths (Fig. 5D). 
3.5. ORM-10962 extends post-repolarization refractoriness 
Using the S1-S2 protocol, we observed that ORM-10962 extended the 
duration of post-repolarization refractoriness (PRR; see Methods 1.1.4 
for the exact definition) (Fig. 6A). We hypothesized that this could be 
Fig. 5. Simulations of heart failure remodelling and alternans. A) Action potential in control and heart failure (HF) condition at 1 Hz pacing, showing APD pro-
longation and loss of notch following the peak in HF. B) Calcium transient in control and HF, showing its prolongation, prolonged time to peak, and reduced 
amplitude. The calcium transient was normalised between 0 and 1 to facilitate comparison: first, the minimum was subtracted from both calcium transients; second, 
both calcium transients were divided by the maximum of the control trace, preserving the ratio of amplitude between control and HF. C) Calcium concentration in the 
network SR showing reduced SR loading in HF. D) Simulation of the effect of heart failure (HF) remodelling and HF + ORM-10962 treatment (50% NCX + 65% ICaL) 
on alternans development. For each model, the minimum and maximum APD90 achieved over two subsequent beats at the given basic cycle length is given, with 
bifurcations indicating alternans. Small-amplitude alternans in the HF condition developed already at bcl of 330 ms. 
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mediated by an indirect reduction of ICaL via ORM-10962, given the 
current’s involvement in cellular excitability [41–43]. The hypothesis 
was tested using the ToR-ORd model with an increased role of ICaL in 
excitability (Methods 2.3). 
The S1-S2 protocol was simulated using single cells with a 50% block 
of NCX and several possible values of reduced ICaL availability. We 
observed that the lower the ICaL availability, the longer the PRR 
(Fig. 6B); this result was also confirmed in a fibre simulation (Appendix 
E). To exclude the possibility that this is due to a chronic effect following 
from pre-pacing in different conditions (e.g. APD change or a change in 
ionic concentrations), an additional modified S1-S2 protocol was 
simulated. There, S1 pacing was carried out in a control ToR-ORd 
model, with ICaL availability changed only for the S2 stimulus. Again, 
cells with reduced ICaL manifested extended PRR (Fig. 6C). In both 
scenarios, this is due to the fact that for a short coupling interval, INa is 
reduced due to partial refractoriness, giving greater importance to ICaL in 
triggering an action potential. When ICaL is reduced, so is the cellular 
excitability. Together, these results demonstrate that the experimentally 
observed extension of PRR under ORM-10962 can stem from an indirect 
reduction of ICaL. 
4. Discussion 
The main findings of this combined experimental and computational 
work are: 1) ORM-10962 attenuates alternans of both action potential 
duration and calcium transient amplitude; however, the protective ef-
fect is not observed for APD80 alternans at very fast pacing rates. 2) 
Three distinct types of APD alternans are observed, revealing type- 
specific response to ORM-10962 with regards to APD80 alternans 
attenuation. 3) ORM-10962 does not markedly change APD restitution, 
and analysis of diastolic intervals suggests that calcium oscillations drive 
alternans in the experiments. 4) the suggested mechanism of calcium 
alternans inhibition by ORM-10962 is via reduced refractoriness of 
sarcoplasmic reticulum release. 5) ORM-10962 increases post- 
repolarization refractoriness, and this may be mediated by indirect L- 
type calcium current reduction following NCX blockade. 
Cardiac alternans is an important arrhythmogenic phenomenon, 
which can be evoked in healthy hearts [44], but is particularly exacer-
bated in heart disease [12–14]. Alternans attenuation is consequently an 
important aim of antiarrhythmic medication, previously targeted 
mainly by SERCA pump overexpression [45]. Here, we demonstrate that 
the NCX blocker ORM-10962 has the potential to attenuate both 
alternans of APD and of calcium transient amplitude, with the alternans 
being calcium-driven. Importantly, our simulations suggest that ORM- 
10962 alternans attenuation could be effective also in the setting of 
heart failure remodelling. 
In this study, we observed three types of APD alternans with regards 
to action potential morphology: ’++’ (APD25 prolongation during 
alternans occurs in the same beats as APD80 prolongation), ’+− ’ 
(APD25 prolongation occurs in the same beats as APD80 shortening), 
and ’+0’ (APD25 alternans occurs in presence of negligible APD80 
alternans). The fact that three distinct morphological patterns of alter-
nans were observed in a single batch of experiments (in a single species 
and a single experimental protocol) suggests at relatively high and 
perhaps surprising intra-species phenotypic heterogeneity. ORM-10962 
showed a tendency towards shifting alternans type to more negative 
type (’++’ to ’+0’ and ’+0’ to ’+− ’) compared to control. Response to 
ORM-10962 with regards to APD80 alternans differed by the type of 
alternans. While APD80 attenuation occurred for the vast majority of 
’++’ alternans recordings, ’+0’ recordings have shown minimal atten-
uation or even alternans promotion (there was not enough data on ’+− ’ 
type to draw any conclusions). Lack of alternans attenuation at APD80 
for ’+0’ alternans is not surprising, given that the ’+0’ type is defined as 
type with little to no alternans at APD80. Consequently, a shift towards 
the ’+− ’ type means that alternans at APD80 can be paradoxically 
promoted by ORM-10962. On the other hand, the negative-shifting ef-
fect of ORM-10962 on the alternans type means that the drug can be 
especially potent for ’++’ alternans, given that it can attenuate under-
lying calcium alternans, as well as shift the APD80 alternans type to-
wards ’+0’, reducing dispersion of repolarization. The ’++’ type of 
alternans is possibly the most frequently reported type of alternans, 
observed in human [44], guinea pig [46,47], cat [48], or rabbit [17,49], 
supporting the relevance of alternans attenuation in this type. Finally, 
the fact that the ’++’ type manifested the greatest absolute amplitude of 
APD80 (with the amplitude being small or minimal for ’+− ’ and ’+0’ 
types) means that clinical testing based on T-wave alternans is likely to 
detect precisely the patients who will benefit the most from hypothetical 
treatment based on NCX blockade. However, further research is needed 
to better characterize and understand the mechanisms (e.g. balance of 
ionic currents or regional differences) underlying the different types of 
alternans observed in this study. 
The experimental results presented in this study suggest that ORM- 
10962 attenuates CaT alternans (as evidenced by measurements in iso-
lated myocytes and by attenuation of APD25 alternans, which is very 
Fig. 6. ORM-10962 extends PRR. A) Experimental data from papillary muscle preparations of the shortest DI which led to formation of an action potential in the S1- 
S2 protocol (n = 6). B) Simulations of S1-S2 protocol under NCX block and ICaL reduction. The leftmost point on each curve determines the PRR in the given 
condition. C) Simulations of S1-S2 protocol where the S1 phase was carried out using control model without any perturbation of NCX and ICaL, with the ICaL reduction 
being introduced only for the S2 beat. 
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likely to be tightly associated with CaT alternans). This is an important 
result, given that analysis of diastolic intervals and restitution suggest 
that APD alternans in the presented experiments is not driven by resti-
tution, but rather by alternans of CaT. The most likely explanation of 
calcium alternans attenuation suggested by computer simulations is the 
altered balance of two factors contributing to the amplitude of the cal-
cium transient: the L-type calcium current and the SR calcium loading. 
While ICaL is indirectly reduced by the NCX blockade [7], our simula-
tions suggest that the SR loading is, in turn, increased. This prediction is 
supported by the fact that ORM-10962 reduces ICaL, but increases the 
calcium transient amplitude [6]. Therefore, there must be an additional 
contributor to the calcium transient amplitude which outweighs ICaL 
reduction, and the increased SR loading is the most likely candidate. 
Such an effect is to be expected from an NCX blocker; the NCX and 
SERCA pumps in the SR are dominant mechanisms of removal of calcium 
from cytosol [2], and when NCX is inhibited, a greater relative role is 
given to SERCA pumps (Diaz et al., 2004), enhancing the reuptake into 
SR (provided the influx via ICaL is not reduced excessively). Enhanced SR 
reuptake was then shown to reduce the refractoriness of calcium release 
from the SR [50]. Given that the refractoriness of release was shown to 
be a potential driver of alternans both experimentally and computa-
tionally [23,51], this could explain experimental observation of alter-
nans inhibition following enhancement of SR reuptake [45,52]. 
Alternans attenuation via NCX inhibition may, in future, be an easier 
avenue towards alternans-aimed antiarrhythmics compared to previ-
ously considered SERCA overexpression. The NCX inhibition can be 
mediated by a channel-blocking drug such as ORM-10962, which can be 
administered or withdrawn as needed, unlike the manipulation of pro-
tein expression. In addition, NCX inhibition may also be anti-arrhythmic 
by preventing triggered activity due to delayed and early after-
depolarisations where NCX is thought to play an important role in their 
initiation [53]. Furthermore, under normal condition, the NCX inhibi-
tion has negligible proarrhythmic effects since it did not or marginally 
influence the ECG, the shape of the action potential and the kinetics of 
the Ca2+ transient [6,54,55]. 
The S1-S2 protocol has revealed that the ORM-10962 extends post- 
repolarization refractoriness (PRR). Computer simulations suggest the 
reduction in L-type calcium current following ORM-10962 exposure as a 
potential contributor, particularly in the setting when INa is reduced. An 
alternative explanation lies in the calcium-based inactivation of fast 
sodium current [56]: it is to be expected that following NCX blockade, 
sub-sarcolemmal calcium concentration would rise due to reduced cal-
cium efflux, inhibiting fast sodium current and trivially extending PRR. 
Future quantitative studies may elucidate the relative contribution of 
these two mechanisms. Localized prolongation of PRR is known to be 
arrhythmogenic in the setting of acute ischemia; however, it was sug-
gested that if PRR extension is global and without a major elevation of 
resting potential, it is antiarrhythmic instead, protecting the heart from 
re-entry [57]. PRR extension could therefore be an additional beneficial 
anti-arrhythmic effect of ORM-10962. 
One interesting aspect of the simulation part of this study is the fact 
that an explicit reduction in ICaL was required to manifest the experi-
mentally observed reduction in ICaL following ORM-10962 treatment. 
The indirect ICaL reduction observed in experiments appears to stem 
from calcium-dependent inactivation of ICaL, given that the effect is 
abolished by the fast buffer BAPTA, or by depletion of SR [7]. At the 
same time, the ToR-ORd showed only a negligible reduction in peak ICaL 
in response to pure NCX block, similarly to other models we tried this 
treatment on (not shown) [27,58,59]. As all these models do represent 
experimental data on calcium-dependent inactivation, the discrepancy 
between experimental results and simulations suggests a gap in our 
understanding of calcium-dependent inactivation of ICaL. 
5. Study limitations 
Our study has the following limitations:  
(i) The action potential measurements were carried out on tissue 
while CaTs were recorded from isolated cells. This may indicate 
that the magnitude and kinetics of action potential alternans 
could not be directly related to CaT alternans. An alternative 
approach would be to use dual calcium-voltage imaging, but this 
approach would have a different set of limitations arising from 
the use of mechanical uncouplers such as blebbistatin [60].  
(ii) The action potential measurements were performed on intact 
ventricular tissue to avoid shortcomings arising from repolari-
zation attenuation caused by enzymatic dissociation. Due to the 
stable repolarization, the alternans could be evoked with 100% 
probability and small APD changes could be detected with high 
fidelity. At the same time, it also means that our action potential 
measurements represent only the endocardial tissue. Other cell 
layers (such as epicardial cells) may have different characteristics 
during alternans. Furthermore, the range of basic cycle lengths 
for the microelectrode measurements in ventricular tissue was 
determined based on pilot data suggesting that alternans will not 
be present at bcl of 250 ms; however, in data collected for the 
study, alternans was also present at bcl of 250 ms. It is conse-
quently impossible to precisely determine the effect of ORM- 
10962 on alternans onset (the slowest frequency at which alter-
nans arises). Finally, we could not pace the single cells used for 
calcium measurements as rapidly as the faster pacing rates in the 
intact preparations, given that a 2:1 block manifested; this is most 
likely a consequence of the cell isolation, which is known to 
prolong APD and thus refractoriness primarily via the reduced 
density of the potassium channels.  
(iii) The ToR-ORd computer model does not spontaneously reduce 
ICaL in response to NCX blockade, (similarly to [27,58,59]), and 
the reduction thus had to be added explicitly. While this suggests 
interesting avenues for further research as discussed above, it is 
clearly a limitation of existing models. In addition, further 
research is needed to create models which could manifest all 
three types of alternans observed in this study (’++’, ’+− ’, ’+0’) 
dependent on their parametrization, allowing further investiga-
tion into the link between CaT and APD alternans. 
6. Conclusions 
Our experimental work and computational mechanistic modelling 
and simulation indicate that the NCX blocker ORM-10962 can attenuate 
alternans in both APD and calcium transient amplitude. This is driven 
primarily by shifting the intracellular calcium balance to increased 
sarcoplasmic reticulum loading, reducing SR release refractoriness, thus 
attenuating alternans. 
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[23] J. Tomek, M. Tomková, X. Zhou, G. Bub, B. Rodriguez, Modulation of cardiac 
alternans by altered sarcoplasmic reticulum calcium release: a simulation study, 
Front. Physiol. 9 (2018) 1306, https://doi.org/10.3389/fphys.2018.01306. 
[24] J. Tomek, A ‘comb’ algorithm for accurate detection of calcium transients and 
action potentials in regularly activating cardiac preparations, BioRxiv. 757294 
(2019), https://doi.org/10.1101/757294. 
[25] J. Tomek, A. Bueno-Orovio, E. Passini, X. Zhou, A. Minchole, O. Britton, 
C. Bartolucci, S. Severi, A. Shrier, L. Virag, A. Varro, B. Rodriguez, Development, 
calibration, and validation of a novel human ventricular myocyte model in health, 
disease, and drug block, Elife. 8 (2019), e48890, https://doi.org/10.7554/ 
eLife.48890. 
[26] E. Grandi, F.S. Pasqualini, D.M. Bers, A novel computational model of the human 
ventricular action potential and Ca transient, J. Mol. Cell. Cardiol. 48 (2010) 
112–121, https://doi.org/10.1016/j.yjmcc.2009.09.019. 
[27] K.H.W.J. ten Tusscher, A.V. Panfilov, Alternans and spiral breakup in a human 
ventricular tissue model, Am. J. Physiol. Heart Circ. Physiol. 291 (2006) 
H1088–H1100, https://doi.org/10.1152/ajpheart.00109.2006. 
[28] J. Heijman, P.G.A. Volders, R.L. Westra, Y. Rudy, Local control of β-adrenergic 
stimulation: Effects on ventricular myocyte electrophysiology and Ca(2+)- 
transient, J. Mol. Cell. Cardiol. 50 (2011) 863–871, https://doi.org/10.1016/j. 
yjmcc.2011.02.007. 
[29] E. Passini, O.J. Britton, H.R. Lu, J. Rohrbacher, A.N. Hermans, D.J. Gallacher, R.J. 
H. Greig, A. Bueno-Orovio, B. Rodriguez, Human in silico drug trials demonstrate 
higher accuracy than animal models in predicting clinical pro-arrhythmic 
cardiotoxicity, Front. Physiol. 12 (2017) 668, https://doi.org/10.3389/ 
fphys.2017.00668. 
[30] R. Coppini, C. Ferrantini, L. Yao, P. Fan, M. Del Lungo, F. Stillitano, L. Sartiani, 
B. Tosi, S. Suffredini, C. Tesi, M. Yacoub, I. Olivotto, L. Belardinelli, C. Poggesi, 
E. Cerbai, A. Mugelli, Late sodium current inhibition reverses electromechanical 
dysfunction in human hypertrophic cardiomyopathy, Circulation. 127 (2013) 
575–584, https://doi.org/10.1161/CIRCULATIONAHA.112.134932. 
[31] J.F. Gomez, K. Cardona, L. Romero, J.M. Ferrero, B. Trenor, Electrophysiological 
and structural remodeling in heart failure modulate arrhythmogenesis. 1D 
simulation study, PLoS One (2014), https://doi.org/10.1371/journal. 
pone.0106602. 
[32] T.H. Fischer, L.S. Maier, S. Sossalla, The ryanodine receptor leak: how a tattered 
receptor plunges the failing heart into crisis, Heart Fail. Rev. 18 (2013) 475–483, 
https://doi.org/10.1007/s10741-012-9339-6. 
[33] T.R. Kolstad, J. van den Brink, N. Macquaide, P.K. Lunde, M. Frisk, J.M. Aronsen, 
E.S. Norden, A. Cataliotti, I. Sjaastad, O.M. Sejersted, A.G. Edwards, G.T. Lines, W. 
E. Louch, Ryanodine receptor dispersion disrupts Ca 2+ release in failing cardiac 
myocytes, Elife (2018), https://doi.org/10.7554/eLife.39427. 
[34] M. Lindner, M.C. Brandt, H. Sauer, J. Hescheler, T. Böhle, D.J. Beuckelmann, 
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[41] S. Rohr, J.P. Kucera, A.G. Kléber, Slow conduction in cardiac tissue, I, Circ. Res. 83 
(1998) 781–794, https://doi.org/10.1161/01.res.83.8.781. 
[42] S. Rohr, J.P. Kucera, Involvement of the calcium inward current in cardiac impulse 
propagation: induction of unidirectional conduction block by nifedipine and 
reversal by bay K 8644, Biophys. J. 72 (1997) 754–766, https://doi.org/10.1016/ 
S0006-3495(97)78710-1. 
[43] R.M. Shaw, Y. Rudy, Ionic mechanisms of propagation in cardiac tissue: roles of the 
sodium and L-type calcium currents during reduced excitability and decreased gap 
junction coupling, Circ. Res. 81 (1997) 727–741, https://doi.org/10.1161/01. 
RES.81.5.727. 
[44] M.L. Koller, S.K.G. Maier, A.R. Gelzer, W.R. Bauer, M. Meesmann, R.F. Gilmour, 
Altered dynamics of action potential restitution and alternans in humans with 
structural heart disease, Circulation. 112 (2005) 1542–1548, https://doi.org/ 
10.1161/CIRCULATIONAHA.104.502831. 
[45] M.J. Cutler, X. Wan, B.N. Plummer, H. Liu, I. Deschenes, K.R. Laurita, R.J. Hajjar, 
D.S. Rosenbaum, Targeted sarcoplasmic reticulum Ca2+ ATPase 2a gene delivery 
to restore electrical stability in the failing heart, Circulation. 126 (2012) 
2095–2104, https://doi.org/10.1161/CIRCULATIONAHA.111.071480. 
[46] X. Wan, K.R. Laurita, E.J. Pruvot, D.S. Rosenbaum, Molecular correlates of 
repolarization alternans in cardiac myocytes, J. Mol. Cell. Cardiol. (2005), https:// 
doi.org/10.1016/j.yjmcc.2005.06.004. 
[47] M.L. Walker, X. Wan, G.E. Kirsch, D.S. Rosenbaum, Hysteresis Effect implicates 
calcium cycling as a mechanism of repolarization alternans, Circulation (2003), 
https://doi.org/10.1161/01.CIR.0000093276.10885.5B. 
[48] J. Hüser, Y.G. Wang, K.A. Sheehan, F. Cifuentes, S.L. Lipsius, L.A. Blatter, 
Functional coupling between glycolysis and excitation-contraction coupling 
underlies alternans in cat heart cells, J. Physiol. (2000), https://doi.org/10.1111/ 
j.1469-7793.2000.00795.x. 
[49] A. Mahajan, Y. Shiferaw, D. Sato, A. Baher, R. Olcese, L.H. Xie, M.J. Yang, P. 
S. Chen, J.G. Restrepo, A. Karma, A. Garfinkel, Z. Qu, J.N. Weiss, A rabbit 
ventricular action potential model replicating cardiac dynamics at rapid heart 
rates, Biophys. J. 94 (2008) 392–410, https://doi.org/10.1529/ 
biophysj.106.98160. 
[50] H.R. Ramay, O.Z. Liu, E.A. Sobie, Recovery of cardiac calcium release is controlled 
by sarcoplasmic reticulum refilling and ryanodine receptor sensitivity, Cardiovasc. 
Res. 91 (2011) 598–605, https://doi.org/10.1093/cvr/cvr143. 
[51] L. Wang, R.C. Myles, N.M. De Jesus, A.K.P. Ohlendorf, D.M. Bers, C.M. Ripplinger, 
Optical mapping of sarcoplasmic reticulum Ca2+ in the intact heart: ryanodine 
receptor refractoriness during alternans and fibrillation, Circ. Res. 114 (2014) 
1410–1421, https://doi.org/10.1161/CIRCRESAHA.114.302505. 
[52] V. Stary, D. Puppala, M. Scherrer-Crosbie, W.H. Dillmann, A.A. Armoundas, 
SERCA2a upregulation ameliorates cellular alternans induced by metabolic 
inhibitions, J. Appl. Physiol. 120 (2016) 865–875, https://doi.org/10.1152/ 
japplphysiol.00588.2015. 
[53] N. Herring, M. Kalla, D.J. Paterson, The autonomic nervous system and cardiac 
arrhythmias: current concepts and emerging therapies, Nat. Rev. Cardiol. (2019), 
https://doi.org/10.1038/s41569-019-0221-2. 
[54] A.S. Farkas, K. Acsai, N. Nagy, A. Tóth, F. Fülöp, G. Seprényi, P. Birinyi, P. 
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